Clinical trial
Intralesional PV-10 Chemoablation of Metastatic Melanoma
NCT00219843 · Provectus Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00219843 |
|---|---|
| Title | Intralesional PV-10 Chemoablation of Metastatic Melanoma |
| Official title | A Phase 1 Safety and Tolerability Study of Intralesional PV-10 Chemoablation in Subjects With Metastatic Melanoma |
| Lead sponsor | Provectus Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | PV-10 (rose bengal disodium, 10%) |
| Enrollment | 20 |
| Start date | Aug 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Aug 23, 2007 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: